Biblio
“Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish.”, Aquat Toxicol, vol. 154, pp. 71-9, 2014.
, “Novel Target Genes of the Ah (Dioxin) Receptor Transcriptional Induction of N-Myristoyltransferase 2”, Cancer research, vol. 61, pp. 8534–8539, 2001.
, “Nucleotide sequence of cDNA encoding bonnet monkey (Macaca radiata) zona pellucida glycoprotein-ZP3”, Reproduction, Fertility and Development, vol. 7, pp. 1209–1212, 1995.
, “Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma”, Blood, vol. 109, no. 9, pp. 3849 - 3855, 2007.
, “Orphan receptor COUP-TF is required for induction of retinoic acid receptor $\beta$, growth inhibition, and apoptosis by retinoic acid in cancer cells”, Molecular and cellular biology, vol. 20, pp. 957–970, 2000.
, “p27Kip1 induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells”, Genes & Development, vol. 13, no. 13, pp. 1742 - 1753, 1999.
, “Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt”, Oncogene, vol. 25, pp. 2974–2986, 2006.
, “Regulation of retinoic acid receptor $\beta$ expression by peroxisome proliferator-activated receptor $\gamma$ ligands in cancer cells”, Cancer Research, vol. 63, pp. 3531–3538, 2003.
, “Regulation of retinoic acid-induced inhibition of AP-1 activity by orphan receptor chicken ovalbumin upstream promoter-transcription factor”, Journal of Biological Chemistry, vol. 277, pp. 21414–21422, 2002.
, “Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target.”, Arch Toxicol, vol. 91, no. 7, pp. 2497-2513, 2017.
, “A Short Nur77-Derived Peptide Converts Bcl-2 from a Protector to a Killer”, Cancer Cell, vol. 14, no. 4, pp. 285 - 298, 2008.
, “A structural switch between agonist and antagonist bound conformations for a ligand-optimized model of the human aryl hydrocarbon receptor ligand binding domain”, Biology, vol. 3, pp. 645–669, 2014.
, “A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain”, Biology, vol. 399, no. 4, pp. 645 - 669, 2014.
, “A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain.”, Biology (Basel), vol. 3, no. 4, pp. 645-69, 2014.
, “Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3′, 4′-dimethoxy-$\alpha$-naphthoflavone”, Molecular pharmacology, vol. 79, pp. 508–519, 2011.
, “TCDD, FICZ, and other high affinity AhR ligands dose-dependently determine the fate of CD4+ T cell differentiation.”, Toxicol Sci, 2018.
, “TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38-MAPK-dependent pathway.”, Oncogene, vol. 24, no. 31, pp. 4975-83, 2005.
, “Unique anti-activator protein-1 activity of retinoic acid receptor $\beta$”, Cancer research, vol. 60, pp. 3271–3280, 2000.
,